Silence Therapeutics plc (NASDAQ:SLN – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $26.74 and last traded at $26.15, with a volume of 7131 shares traded. The stock had previously closed at $26.25.
Analysts Set New Price Targets
A number of brokerages recently issued reports on SLN. BMO Capital Markets began coverage on Silence Therapeutics in a research report on Wednesday, January 31st. They issued an “outperform” rating and a $67.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research report on Thursday, February 22nd.
Get Our Latest Stock Report on Silence Therapeutics
Silence Therapeutics Trading Down 3.4 %
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Artal Group S.A. grew its stake in shares of Silence Therapeutics by 236.6% during the second quarter. Artal Group S.A. now owns 1,700,000 shares of the company’s stock valued at $9,350,000 after buying an additional 1,194,926 shares during the last quarter. Vivo Capital LLC bought a new stake in shares of Silence Therapeutics in the fourth quarter worth about $8,862,000. Lynx1 Capital Management LP bought a new stake in shares of Silence Therapeutics in the third quarter worth about $2,315,000. M28 Capital Management LP grew its stake in shares of Silence Therapeutics by 149.3% in the second quarter. M28 Capital Management LP now owns 363,800 shares of the company’s stock worth $2,001,000 after purchasing an additional 217,900 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Silence Therapeutics by 27.1% in the first quarter. Goldman Sachs Group Inc. now owns 965,815 shares of the company’s stock worth $18,350,000 after purchasing an additional 205,815 shares during the last quarter. Institutional investors own 64.27% of the company’s stock.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's mRNAi GOLD GalNAc Oligonucleotide Discovery platform that is used to target specific disease-associated genes in the liver.
Recommended Stories
- Five stocks we like better than Silence Therapeutics
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Samsara Stock Nears Major Breakout Ahead of Upcoming Earnings
- Golden Cross Stocks: Pattern, Examples and Charts
- Paymentus Is a Tech Stock You’re Going To Hear a Lot More About
- How to Buy Cheap Stocks Step by Step
- How to Use Options Collars to Hedge Your Stock Gains
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.